2/24/2014 9:03:32 AM
VANCOUVER, British Columbia, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a developer of RNA interference (RNAi) therapeutics, today announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Québec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-10.
Help employers find you! Check out all the jobs and post your resume.
comments powered by